The release of a model low-dose drug (riboflavine) from hard gelatin capsule formulations.
The in vitro release of a model low dose drug, riboflavine, from hard gelatin capsules, formulated with a range of diluents, in the absence and presence of magnesium stearate (0.5, 1.0 and 2.0% w/w), has been assessed by a dissolution technique. Comparison of the values of the time for 50% of the drug content of the capsule to appear in solution T50, by analysis of variance, indicated that the type of diluent significantly influenced the drug release. Irrespective of the magnesium stearate content, the diluents could be ranked in the following order of effectiveness: Primojel greater than sodium bicarbonate greater than Avicel congruent to Dri-flo starch congruent to lactose greater than Emcompress congruent to kaolin greater than starch. Correction of the T50 values for possible adsorption of riboflavine onto the water insoluble diluents, using experimentally determined adsorption isotherms, altered the relative order of effectiveness of the diluents to Primojel greater than sodium bicarbonate greater than kaolin congruent to lactose greater than Avicel congruent to Dri-flo starch greater than Emcompress greater than starch. Comparison of the urinary excretion of riboflavine, after administration of capsule formulations containing lactose, Emcompress or kaolin as the diluent, to volunteers, suggests that the dissolution results not corrected for adsorption provide a better indication of the in vivo performance of the formulations.
D002214:Capsules; D002626:Chemistry, Pharmaceutical; D004339:Drug Compounding; D006801:Humans; D012256:Riboflavin / Q000008:administration & dosage / Q000032:analysis / Q000378:metabolism; D012995:Solubility; D013696:Temperature; D013997:Time Factors
D002214:Capsules; D012256:Riboflavin